Welcome to

The Nordic Society of
Gynaecological Oncology

The Nordic Society of
Gynaecological Oncology

 

Line Bjørge

President of NSGO

Mansoor Raza Mirza

Medical Director of NSGO-CTU

Members Application

Full membership is open to any individual in a Nordic country, who is professionally or scientifically active in the field of gynaecological cancer.

Recruitment Status

Trial recruitment status - updated every month

Trial overview

Information & Design / Ongoing Trials

NSGO-CTU Sites

An Overview Over Active Sites

Publication overview

Contributions from members of NSGO.

NSGO Annual Meeting

Join us in Iceland, 2023

Open Book

NSGO-CTU Investigator Meeting

Copenhagen
2022

Investigator Meeting Program 2022
Mar 21
0:00
NSGO-CTU Scientific Commite
Apr 18
0:00
NSGO-CTU Scientific Commite
May 16
0:00
NSGO-CTU Scientific Commite
Jun 15
All day
NSGO ANNUAL MEETING

ESMO 2022 – Line Bjørge: Some of the patients with ovarian cancer who received olaparib were cured. The SOLO-1 study shows that 67 percent of patients with advanced ovarian cancer with BRCA mutations who were treated with the PARP inhibitor Olaparib were alive after 7 years compared to 47 percent in the placebo group. – Some of the patients with ovarian cancer who received olaparib were cured. This is a big step forward for our patients.

Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses recent improvements in immune-oncology, specifically immune checkpoint inhibitors, for patients with endometrial or cervical cancer. There have been big developments in this field in recent years, with several therapies being approved in the EU and USA. Several Phase III trials are likely to produce interesting data in the near future. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague